Chinn Amy M, Salmerón Cristina, Lee Jihyung, Sriram Krishna, Raz Eyal, Insel Paul A
Department of Pharmacology, University of California, San Diego, La Jolla, CA, United States.
Department of Medicine, University of California, San Diego, La Jolla, CA, United States.
Front Pharmacol. 2022 Mar 21;13:833832. doi: 10.3389/fphar.2022.833832. eCollection 2022.
Chronic decreases in the second messenger cyclic AMP (cAMP) occur in numerous settings, but how cells compensate for such decreases is unknown. We have used a unique system-murine dendritic cells (DCs) with a DC-selective depletion of the heterotrimeric GTP binding protein Gα-to address this issue. These mice spontaneously develop Th2-allergic asthma and their DCs have persistently lower cAMP levels. We found that phosphodiesterase 4B (PDE4B) is the primary phosphodiesterase expressed in DCs and that its expression is preferentially decreased in Gα-depleted DCs. PDE4B expression is dynamic, falling and rising in a protein kinase A-dependent manner with decreased and increased cAMP concentrations, respectively. Treatment of DCs that drive enhanced Th2 immunity with a PDE4B inhibitor ameliorated DC-induced helper T cell response. We conclude that PDE4B is a homeostatic regulator of cellular cAMP concentrations in DCs and may be a target for treating Th2-allergic asthma and other settings with low cellular cAMP concentrations.
第二信使环磷酸腺苷(cAMP)的慢性减少在多种情况下都会发生,但细胞如何补偿这种减少尚不清楚。我们使用了一种独特的系统——对异源三聚体GTP结合蛋白Gα进行DC选择性耗竭的小鼠树突状细胞(DC)来解决这个问题。这些小鼠会自发发展为Th2型过敏性哮喘,并且它们的DC中cAMP水平持续较低。我们发现磷酸二酯酶4B(PDE4B)是DC中表达的主要磷酸二酯酶,并且其表达在Gα耗竭的DC中优先降低。PDE4B的表达是动态的,分别随着cAMP浓度的降低和升高以蛋白激酶A依赖的方式下降和上升。用PDE4B抑制剂处理驱动Th2免疫增强的DC可改善DC诱导的辅助性T细胞反应。我们得出结论,PDE4B是DC中细胞cAMP浓度的稳态调节因子,可能是治疗Th2型过敏性哮喘和其他细胞cAMP浓度低的情况的靶点。